The Wesleyan Growth Trust aims to produce capital appreciation and an increasing income from a diversified portfolio of securities, over a medium to long-term period.
Name | % Net Assets |
---|---|
HSBC | 5.7% |
GlaxoSmithKline | 5.0% |
AstraZeneca | 2.9% |
Royal Bank of Scotland | 2.1% |
Diageo | 2.0% |
Unilever | 1.9% |
Lloyds TSB | 1.6% |
Aviva | 1.5% |
Barclays | 1.4% |
Prudential | 1.3% |
Key | % Net Assets |
---|---|
HSBC | 5.7% |
GlaxoSmithKline | 5.0% |
AstraZeneca | 2.9% |
Royal Bank of Scotland | 2.1% |
Other | 84.3% |
Date | n/a |
---|---|
Bid | 0.00 |
Offer | 0.00 |
Currency | n/a |
Change | 0.00 |
% | n/a |
YTD change | 0.00 |
YTD % | n/a |
Fund Inception | 11/12/1995 |
---|---|
Fund Manager | Clive Ward |
TER | - |
Minimum Investment | |
---|---|
Initial | 2000 |
Additional | n/a |
Savings | 100 |
Charges | |
---|---|
Initial | 4.00% |
Annual Mang't | 1.25% |
Exit | n/a |
Name | % |
---|---|
Standard deviation | 0.02 |
Sharpe ratio | 0.11 |
You are here: research